相关实验视频

Updated: Jul 30, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

在接受teprotumumab治疗的患者中,听力功能障碍的频率和模式

Jamie A Keen¹, Tatiana Correa², Chau Pham¹

¹Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa.

|August 11, 2023

概括

治疗甲状腺眼病的teprotumumab治疗可能会导致听力功能障碍,特别是在老年患者和更高频率. 定期的听力测试对于监测和管理这些耳毒性影响至关重要.

科学领域:

眼科和内分泌学眼科和内分泌学
听力学和耳鼻喉学

背景情况:

甲状腺眼睛疾病 (TED) 是一种影响轨道的自身免疫性疾病.
德鲁马布是一种新型的生物疗法,已获批准用于中度至重度TED.
需要进一步调查teprotumumab的潜在副作用,包括听力功能障碍.

研究的目的:

为了调查治疗teprotumumab的患者中听力损失的发生率和特征.
分析听力学数据以确定与teprotumumab治疗相关的听力损失模式.

主要方法:

采用了一个非比较的案例系列设计.
在给22名患者 (44个耳朵) 输注teprotumumab前后进行了听力学测试 (听力图).
听力损失被定义为分贝听力值的显著变化或满足耳毒性标准.

主要成果:

在38.6%的耳朵 (50%的患者) 观察到符合耳毒性标准的听力损失.
显著的听力损失发生在高频和中频,但不是低频.
老年患者更有可能经历治疗后的听力损失.

结论:

德鲁马布显著影响听力功能,特别是在高频率和老年人中.
对于接受teprotumumab治疗的患者来说,听力监测是必不可少的,以检测和管理听力变化.
建议在teprotumumab治疗期间使用标准化的听力监测协议.

关键词:

听力学听力学是指听力学.听力损失听力损失耳部毒性耳部毒性这就是为什么Teprotumumab.甲状腺眼睛疾病甲状腺眼病

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.